{"id":"zibotentan-dapagliflozin","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of diabetic ketoacidosis"},{"rate":"null","effect":"Hypotension"},{"rate":"null","effect":"Hyperkalemia"}]},"_chembl":{"chemblId":"CHEMBL429910","moleculeType":"Small molecule","molecularWeight":"408.88"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Zibotentan works by blocking the action of endothelin-1, a peptide that causes blood vessels to constrict. Dapagliflozin, on the other hand, inhibits the sodium-glucose cotransporter 2, reducing glucose reabsorption in the kidneys and promoting glucose excretion in the urine.","oneSentence":"Zibotentan/Dapagliflozin is a combination of a selective endothelin receptor antagonist and a sodium-glucose cotransporter 2 inhibitor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:19.019Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic heart failure"}]},"trialDetails":[{"nctId":"NCT06087835","phase":"PHASE3","title":"Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-11-07","conditions":"Chronic Kidney Disease With High Proteinuria","enrollment":1835},{"nctId":"NCT07404137","phase":"PHASE1","title":"A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-02-16","conditions":"Healthy Participants","enrollment":26},{"nctId":"NCT06269484","phase":"PHASE2","title":"A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-02-15","conditions":"Liver Cirrhosis","enrollment":73},{"nctId":"NCT06942910","phase":"PHASE2","title":"A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-05-07","conditions":"Chronic Kidney Disease With High Proteinuria","enrollment":224},{"nctId":"NCT05516498","phase":"PHASE2","title":"Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2022-10-31","conditions":"Liver Cirrhosis","enrollment":205},{"nctId":"NCT05570305","phase":"PHASE2","title":"Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2022-10-06","conditions":"Chronic Kidney Diseases","enrollment":42},{"nctId":"NCT04724837","phase":"PHASE2","title":"Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-04-28","conditions":"Chronic Kidney Disease","enrollment":542},{"nctId":"NCT04991571","phase":"PHASE1","title":"Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-07-29","conditions":"Chronic Kidney Disease","enrollment":27}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Zibotentan/Dapagliflozin","genericName":"Zibotentan/Dapagliflozin","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Zibotentan/Dapagliflozin is a combination of a selective endothelin receptor antagonist and a sodium-glucose cotransporter 2 inhibitor. Used for Chronic heart failure.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}